How many clinical trials are tracked of plerixafor?

22 trials are tracked, 1 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

plerixafor

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of plerixafor

22 trials tracked of plerixafor: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 40 citations.

22Trials tracked

2Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 3 2 Phase 2 18 Phase 1 2

Phase 3 Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Completed · 40 cited
Phase 3 Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma Completed
Phase 2 Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed
Phase 2 Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma Completed
Phase 2 Collection of Transplant Stem Cells for Plasma Cell Myeloma Completed
Phase 2 Alteration in Timing of Plerixafor Administration Completed

Show 16 more trials

Phase 2 Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells Completed
Phase 2 Plerixafor for Stem Cell Mobilization in Normal Donors Completed
Phase 2 Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors Completed
Phase 2 MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma Completed
Phase 2 Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Completed
Phase 2 Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia Completed
Phase 2 Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer Completed
Phase 2 Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin Completed
Phase 2 Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant Completed
Phase 2 Scleroderma Treatment With Autologous Transplant (STAT) Study Completed
Phase 2 A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor Completed
Phase 2 Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection Completed
Phase 2 Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma Completed
Phase 2 Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant Completed
Phase 1 Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment Completed
Phase 1 Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Completed

Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.